Accela Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 24-10-2024
- Paid Up Capital ₹ 0.15 M
as on 24-10-2024
- Company Age 14 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -31.03%
(FY 2023)
- Profit -34.57%
(FY 2023)
- Ebitda -31.63%
(FY 2023)
- Net Worth 16.13%
(FY 2023)
- Total Assets -28.73%
(FY 2023)
About Accela Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.15 M, as per Ministry of Corporate Affairs (MCA) records.
Dinesh Bothra and Pragati Bothara serve as directors at the Company.
- CIN/LLPIN
U24232PN2010PTC136759
- Company No.
136759
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jul 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Accela Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dinesh Bothra  | Director | 05-Jul-2010 | Current |
| Pragati Bothara | Director | 30-Mar-2022 | Current |
Financial of Accela Pharmaceuticals.
Accela Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 31.03% decrease. The company also saw a substantial fall in profitability, with a 34.57% decrease in profit. The company's net worth Soared by an impressive increase of 16.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Accela Pharmaceuticals?
In 2023, Accela Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Indo-Bio Active Labs Private LimitedActive 25 years 10 monthsDinesh Bothra and Pragati Bothara are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Accela Pharmaceuticals?
Unlock and access historical data on people associated with Accela Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Accela Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Accela Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
